BREZTRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
RELEASE THE POWER OF
BREZTRI is not indicated for the relief of acute bronchospasm or for the treatment of asthma.
BREZTRI significantly reduced the annual rate of moderate or severe COPD exacerbations vs LAMA/LABA (RR=0.76; 95% CI: 0.69, 0.83; P<0.0001) and ICS/LABA (RR=0.87; 95% CI: 0.79, 0.95; P=0.0027) in a 52-week study.1* Annual rate estimate: BREZTRI 1.08; LAMA/LABA: 1.42; ICS/LABA 1.24.1
*Moderate exacerbations were defined as those leading to treatment with systemic corticosteroids and/or antibiotics, and severe exacerbations were defined as those resulting in hospitalization or death.
BREZTRI IS FOR PATIENTS WITH COPD REGARDLESS OF THEIR RECENT EXACERBATION HISTORY.1-4†
†BREZTRI was studied in symptomatic patients with and without a history of moderate or severe exacerbations in the previous year.